Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians
- PMID: 38604202
- DOI: 10.1016/S2352-3018(24)00063-8
Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians
Abstract
In individuals receiving antiretroviral therapy (ART), persistent low-level viraemia not attributed to suboptimal ART adherence, detrimental pharmacological interactions, or drug resistance is referred to as non-suppressible viraemia (NSV). This Review presents recent findings in the virological characterisation of NSV, revealing that it consists of one or a few identical populations of plasma viruses without signs of evolution. This finding suggests that NSV originates from virus production by expanded HIV-infected cell clones, reflecting the persistence of the HIV reservoir despite ART. We discuss knowledge gaps regarding the management and the clinical consequences of NSV. The prevalence of NSV remains to be precisely determined and there is very little understanding of its effects on virological failure, HIV transmission, secondary inflammation, morbidity, and mortality. This issue, along with the absence of specific recommendations for the management of NSV in HIV clinical guidelines, underscores the complexities involved in treating individuals with NSV.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests AE-C has received payment or honoraria for presentations from Gilead Sciences. RM has received payment or honoraria for presentations, and advisory fees; has participated on advisory boards; and has received support for attending meetings from Gilead Sciences, ViiV Healthcare, Janssen, Thera Technologies, GlaxoSmithKline, and Merk Sharp & Dohme. AP-M has received payment or honoraria for presentations and support for attending meetings from ViiV Healthcare, Gilead Sciences, and Merk Sharp & Dohme. FP has received consulting and speaker fees and support for attending meetings from Gilead Sciences, Janssen, Merk Sharp & Dohme, and ViiV Healthcare. JRA has received consulting fees and support for attending meetings from Gilead Sciences, ViiV Healthcare, Aelix, Janssen, and Merk Sharp & Dohme. All other authors declare no competing interests.
Similar articles
-
Viral and host mediators of non-suppressible HIV-1 viremia.Nat Med. 2023 Dec;29(12):3212-3223. doi: 10.1038/s41591-023-02611-1. Epub 2023 Nov 13. Nat Med. 2023. PMID: 37957382 Free PMC article.
-
Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure.Curr HIV/AIDS Rep. 2023 Dec;20(6):428-439. doi: 10.1007/s11904-023-00674-w. Epub 2023 Nov 13. Curr HIV/AIDS Rep. 2023. PMID: 37955826 Free PMC article. Review.
-
Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.Antivir Ther. 2013;18(1):39-43. doi: 10.3851/IMP2323. Epub 2012 Aug 22. Antivir Ther. 2013. PMID: 22914318 Free PMC article. Clinical Trial.
-
Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).Antivir Ther. 2015;20(6):655-60. doi: 10.3851/IMP2949. Epub 2015 Mar 4. Antivir Ther. 2015. PMID: 25735799
-
Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis.Sex Transm Infect. 2024 Oct 17;100(7):460-468. doi: 10.1136/sextrans-2024-056198. Sex Transm Infect. 2024. PMID: 39288983 Free PMC article.
Cited by
-
PLGA-Encapsulated Elvitegravir and Curcumin Modulates ART Penetration, Oxidative Stress, and Inflammation.Brain Sci. 2025 Mar 21;15(4):328. doi: 10.3390/brainsci15040328. Brain Sci. 2025. PMID: 40309788 Free PMC article.
-
Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports.Retrovirology. 2025 Apr 18;22(1):6. doi: 10.1186/s12977-025-00662-5. Retrovirology. 2025. PMID: 40251661 Free PMC article.
-
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?Biomolecules. 2025 Mar 5;15(3):378. doi: 10.3390/biom15030378. Biomolecules. 2025. PMID: 40149913 Free PMC article. Review.
-
Prolonged non-suppressible viremia sustained by a clonally expanded, genomically defective provirus with an immune-evasive HIV protein expression profile.bioRxiv [Preprint]. 2025 May 16:2025.05.16.654538. doi: 10.1101/2025.05.16.654538. bioRxiv. 2025. PMID: 40462973 Free PMC article. Preprint.
-
Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241306484. doi: 10.1177/23259582241306484. J Int Assoc Provid AIDS Care. 2024. PMID: 39711049 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical